Profile image
Story Views

Last Hour:
Last 24 Hours:

B-Cell Non-Hodgkin Lymphoma H2 2016 Therapeutics Review Featuring Drug Profiles, Latest Dormant Projects, Product Development, News & Press Releases

Thursday, November 17, 2016 3:08
% of readers think this story is Fact. Add your two cents.

Latest B-Cell Non-Hodgkin Lymphoma Pipeline Review, H2 2016, provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.
B-Cell Non-Hodgkin Lymphoma therapeutics industry report provides comprehensive information on the therapeutics under development for B-Cell Non-Hodgkin Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Non-Hodgkin Lymphoma and features dormant and discontinued projects.

Browse more detail information about B-Cell Non-Hodgkin Lymphoma market report at:

Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. The two main types of lymphocytes are B lymphocytes (B cells) and T lymphocytes (T cells). Cancer that starts from B lymphocytes (B cells) is known as B Cell Non-Hodgkin Lymphoma. Common signs and symptoms of B Cell Non-Hodgkin Lymphoma include swelling of the lymph nodes (which is often but not always painless), fever, night sweats, unexplained weight loss and lack of energy. Treatment includes surgery, radiation therapy and chemotherapy.  The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key players in B-Cell Non-Hodgkin Lymphoma – Pipeline Review, H2 2016:

  • 3SBio Inc.
  • AB Science SA
  • AbbVie Inc
  • Acetylon Pharmaceuticals, Inc.
  • Actinium Pharmaceuticals, Inc.
  • ADC Therapeutics Sarl
  • Affimed GmbH
  • Altor BioScience Corporation
  • Amgen Inc.
  • arGEN-X BV
  • Ariad Pharmaceuticals, Inc.
  • Arrien Pharmaceuticals, LLC
  • Arvinas, Inc.
  • Asana BioSciences, LLC
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Aurigene Discovery Technologies Limited

And Others

Get a PDF Sample of B-Cell Non-Hodgkin Lymphoma Market Research Report at:

Key Topics Covered:
2.B-Cell Non-Hodgkin Lymphoma Overview
3.B-Cell Non-Hodgkin Lymphoma Therapeutics Development
4.Pipeline Products for B-Cell Non-Hodgkin Lymphoma – Overview
5.Pipeline Products for B-Cell Non-Hodgkin Lymphoma – Comparative Analysis
6.B-Cell Non-Hodgkin Lymphoma – Therapeutics under Development by Companies
7.B-Cell Non-Hodgkin Lymphoma – Therapeutics under Investigation by Universities/Institutes
8.B-Cell Non-Hodgkin Lymphoma Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.B-Cell Non-Hodgkin Lymphoma – Products under Development by Companies
13.B-Cell Non-Hodgkin Lymphoma – Products under Investigation by Universities/Institutes
14.B-Cell Non-Hodgkin Lymphoma – Companies Involved in Therapeutics Development
15.B-Cell Non-Hodgkin Lymphoma Drug Profiles
16.B-Cell Non-Hodgkin Lymphoma Dormant Projects
17.B-Cell Non-Hodgkin Lymphoma Discontinued Products
18.B-Cell Non-Hodgkin Lymphoma Featured News & Press Releases
And Continue…

Get Discount on B-Cell Non-Hodgkin Lymphoma Market Research Report at:

This research study help to:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for B-Cell Non-Hodgkin Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding B-Cell Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


About Absolute Report:

Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.


Mr. Ameya Pingaley

Absolute Reports

+1-408 520 9750

Email –


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.